III. REQUESTED DOCUMENTATION 
A. CLINICAL PROTOCOL: Attached (Appendix A) 
B. U.T. M.D. ANDERSON HUMAN SUBJECTS COMMITTEE; The protocol 
was approved by the Division of Medicine Pre-Review Committee 
pending revisions and the protocol will then be submitted to the 
institution's Human Subjects Committee (Appendix B) . 
C. ONE-PAGE SCIENTIFIC ABSTRACT; Attached (Appendix C) 
D. ONE-PAGE NON-TECHNICAL ABSTRACT; Attached (Appendix D) 
E. CURRICULUM VITAE; Attached (Appendix E) 
F. OTHER FEDERAL AGENCIES INVOLVED IN REVIEW; None 
G. OTHER MATERIAL; None 
IV. REPORTING REQUIREMENTS 
A. Serious adverse effects of treatment (grade III or IV 
toxicity ) , any unexpected toxicity not seen with transplantation 
alone, and any evidence of leukemia, leukemia in solid tumors, or 
patient deaths, will be reported immediately. 
B. Progress reports will be made to the subcommittee and RAC 
at six-months interval. 
REFERENCES 
1. Kasid, A., Morechi, S., Aeberold, P. , Cornetta, K. , Culver, 
K. , Freeman, S., Director, E., Lotze, M.T., Blaise, R.M. , 
Anderson, W.F., and Rosenberg, S. Proc. Natl. Acad. Sci. USA 
^;473-477, 1990. 
2. Osborne, W.R.A., Hock, R.A. , Kolecko, M. , and Miller, A.D. 
Human Gene Therapy 1:31-42, 1990. 
3. Wyngaarden, J. Federal Registry, Volume 54, No. 47, p. 10508, 
March 13, 1989. 
Recombinant DNA Research, Volume 14 
[763] 
